Avant Brands Inc. (TSX: AVNT) posted record financial results for fiscal 2024 ending Nov. 30, with strong growth coming from expanded international sales as exports make up two-thirds of the company’s net revenue these days.

The Canadian producer brought in $40 million in gross revenue for the year, up 32% from the previous year. But after subtracting $4.2 million in excise taxes, the net revenue was $35.8 million, up 36%, the company reported.

“Record revenues, significant international growth, and improved adjusted net income – fiscal 2024 was a landmark year for Avant Brands,” founder and CEO Norton Singhavon said in a statement. “We are focused on building on this success and creating long-term value for our stakeholders.”

The company’s export wholesale revenue saw the biggest jump, climbing 107% to C$19.4 million versus fiscal 2023, as Avant pushed more aggressively into markets abroad – especially in Australia, Germany, and Israel. Export sales in the fourth quarter hit a record C$7.3 million, a 352% increase over the same period last year and now make up 66% of the company’s net revenue.

Export wholesale revenue isn’t subject to domestic excise taxes, which is part of why the company is shifting its strategy toward international markets.

Cannabis production rose 19% to 12,643 kilograms, while sales volume nearly doubled with a 91% increase to 13,560 kilograms. The fourth quarter showed particularly strong sales with a 244% increase in cannabis volume versus the same period in 2023.

Despite the sales gains, Avant posted a gross loss of C$1.8 million in the fourth quarter, down from a C$1 million profit in the fourth quarter of 2023. The company said the decrease came from “non-cash impacts to biological asset valuations,” though noted these were partially offset by increased revenues.

For the full year, the company reported a net loss of C$22.5 million, versus a C$5.2 million loss in fiscal 2023. The increased loss was largely attributed to a C$6 million goodwill impairment charge and a C$3.8 million impairment on construction in progress.

The company noted its fourth straight quarter of positive adjusted EBITDA, which reached C$2.3 million in the fourth quarter. Adjusted net income hit C$2.7 million for the quarter. Still, auditors in filings noted a “material uncertainty related to going concern,” related to the company’s accumulated deficit of C$88 million as of Nov. 30, 2024.

For fiscal 2025, the company plans to grow further in existing international markets while exploring new territories including the Czech Republic, Poland, Switzerland, and the UK. Avant is also looking for partnerships with other Canadian producers to grow their strains under contract to meet rising global demand.

“This initiative will supplement existing production capacity and ensure a consistent supply of high-quality products to international clients,” the company said in a news release.

Canadian cannabis producer Avant Brands Inc. (TSX:AVNT) (OTCQX: AVTBF) reported record third-quarter revenues on Tuesday, driven by surging international demand on its end.

The company posted gross revenue of C$9.6 million for the quarter ended Aug. 31, up 27% from a year earlier. Net revenue rose 30% to C$8.5 million. Net loss for the third quarter was C$2.5 million, compared with a year-ago net profit of C$1.3 million.

Avant’s export wholesale revenue more than doubled to C$5.1 million, outpacing domestic recreational sales for the first time.

“Avant Brands is rapidly establishing itself as a leader in the global cannabis market,” founder and CEO Norton Singhavon said in a statement. “Our strong international sales growth, coupled with new licensing agreements and partnerships, positions us for continued success.”

The company reported record cannabis production of 3,441 kilograms, up 5% year-over-year. Cannabis sold nearly doubled to 3,087 kilograms on increased international shipments.

While exports boomed, recreational sales in Canada fell 30% to C$2.8 million. During the quarter, Avant continued to streamline its offerings to focus on “high-performing and profitable core items,” the company said.

Avant had also inked nine international deals this year, eyeing expansion in markets like Australia and Germany.

“Along with new opportunities developing in the Czech Republic, Poland, Switzerland and the U.K. … these markets, with a combined population exceeding 250 million, present a substantial growth opportunity for Avant,” it said in a news release.

Gross profit fell to C$1 million from C$5 million a year ago, largely due to biological asset valuation impacts. Adjusted EBITDA reached C$2.1 million, marking the third straight quarter above C$2 million, it said.

Avant’s cash balance improved by C$2.4 million year-to-date, versus a C$5.1 million reduction in the same period last year. The company generated C$1.7 million in operating cash flow year-to-date.

Avant recently licensed its blk mkt brand in Australia, adding to deals in Germany, Israel and Switzerland.

It could be rescheduling hopes or just more optimism in general, but it seems investors are warming up to cannabis again. In just the past couple of weeks, more companies have announced huge private placements and increased offerings. Is this an early sign of green shoots from credit markets?

One example: On July 18, Jones Soda Co. (CSE: JSDA, QTCQB: JSDA) upsized its private placement twice to satisfy the thirst for the stock. What began as a $3 million offering, got bumped up to $4 million and then again to $5 million.

“Based on strong demand, we are pleased to increase the size of the private placement to allow more interested parties the opportunity to participate,” CEO David Knight said just a week ago.

Jones said that its focus in 2024 was sales growth with plans to expand the Jones Soda glass bottle business in existing and new sales channels, expand the fountain program in the United States and Canada, and grow the Mary Jones brand, which includes tetrahydrocannabinol (THC) and cannabidiol (CBD)-infused beverages, edibles, and other related products.

Other recent deals

Also this week, Willow Biosciences Inc.(TSX: WLLW) (OTCQB: CANSF) closed its previously announced brokered private placement offering of 16,397,365 units at a price of $0.10 per unit for aggregate gross proceeds of $1,639,736.50. Dr. Chris Savile, president and chief executive officer of Willow said, “The proceeds provide the company with the funds needed to continue execution of our programs and partnerships through to commercial realization that are anticipated in 2024 and into 2025”.

Not wanting to be left out of the party, Avant Brands Inc. (TSX: AVNT)(OTCQX: AVTBF) announced the terms of a proposed non-brokered private placement of unsecured convertible debenture units at a price of $1,000 per convertible debenture unit for gross proceeds of up to C$3.9 million. That follows a C$2.39 million private placement closed on June 3, according to regulatory filings. The company also restructured some debt during the quarter, including extending a convertible debenture’s maturity.

Ascend Wellness Holdings Inc. (CSE: AAWH-U.CN) (OTCQX: AAWH) closed its previously announced private placement of $235 million of 12.75% senior secured notes due in 2029. The company used the net proceeds of the notes, together with cash on hand, to prepay $215 million of principal amounts outstanding under its existing term loan.

“Ascend’s successful refinancing signals an opening of the credit markets, and we expect other solid MSOs to follow suit,” Viridian Capital Advisors’ analysts wrote. “In particular, GTI has a $275 million term loan maturing on 4/25, and we expect the company to take action to refinance that relatively soon.”

Not a minute too soon

Viridian also found that capital fundraising activity in the marijuana and psychedelics industries had dropped by almost 40% in the last year. By sheer dollar amount, fundraising is down nearly 50%.

As the comment period for rescheduling cannabis from a Schedule 1 drug under the Controlled Substances Act to a Schedule 3 drug draws to a close, interest in the space looks to be growing again. The price of the AdvisorShares Pure U.S. Cannabis ETF has risen from a recent low of $6.98 to sell lately at $7.70.

On Monday, Water Tower Research analyst Jesse Redmond wrote, “It was a good week for cannabis stocks, with the US cannabis MSOS ETF gaining 6.15% and global YOLO increasing 5.15%. The Cannabist (OTCQX: CBSTF) +16.67% was the biggest winner among the larger MSOs, while MariMed (OTCQX: MRMD) -10.53% lost the most.”